Trial reportAntimicrobial agents and chemotherapy2000
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
Trial report in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 106 citations in OpenAlex.
- Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza.Antimicrobial agents and chemotherapy · 2013Trial
- Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation.Antimicrobial agents and chemotherapy · 2000Trial
- Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy.Microorganisms · 2023Review
- Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus.Molecules (Basel, Switzerland) · 2020Article
- Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.Frontiers in microbiology · 2018Article
- High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity.PloS one · 2016Article
- Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.Journal of virology · 2015Article
- Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.Antimicrobial agents and chemotherapy · 2013Article
- Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.Medical microbiology and immunology · 2012Article
- Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.Antimicrobial agents and chemotherapy · 2010Article
- Animal models for the study of influenza pathogenesis and therapy.Antiviral research · 2009Review
- Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.PLoS pathogens · 2008Article
- Avian influenza virus infections in humans.Chest · 2006Review
- Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.Journal of clinical microbiology · 2005Article
- Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2004Article
- Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.Clinical and diagnostic laboratory immunology · 2004Article
- Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors.Journal of virology · 2003Article
- Selective incorporation of influenza virus RNA segments into virions.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.Journal of clinical microbiology · 2003Article
- Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy.Paediatric drugs · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zanamivir is a highly selective neuraminidase (NA) inhibitor with demonstrated clinical efficacy against influenza A and B virus infections. In phase II clinical efficacy trials (NAIB2005 and NAIB2008), virological substudies showed mean reductions in virus shedding after 24 h of treatment of 1.5 to 2.0 log(10) 50% tissue culture infective doses compared to a placebo, with no reemergence of virus after the completion of therapy. Paired isolates (n = 41) obtained before and during therapy with zanamivir demonstrated no shifts in susceptibility to zanamivir when measured by NA assays, although for a few isolates NA activity was too low to evaluate. In plaque reduction assays in MDCK cells, the susceptibility of isolates to zanamivir was extremely variable even at baseline and did not correlate with the speed of resolution of virus shedding. Isolates with apparent limited susceptibility to zanamivir by plaque reduction proved highly susceptible in vivo in the ferret model. Further sequence analysis of paired isolates revealed no changes in the hemagglutinin and NA genes in the majority of isolates. The few changes observed were all natural variants. No amino acid changes that had previously been identified in vitro as being involved with reduced susceptibility to zanamivir were observed. These studies highlighted problems associated with monitoring susceptibility to NA inhibitors in the clinic, in that no reliable cell-based assay is available. At present the NA assay is the best available predictor of susceptibility to NA inhibitors in vivo, as measured in the validated ferret model of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.